Jiangsu Yahong Meditech Co., Ltd. (688176)

Overview

Jiangsu Yahong Meditech Co., Ltd., founded in 2010 and headquartered in Shanghai, China, is a biopharmaceutical company focused on the research and development, production, and commercialization of innovative drugs. The company is dedicated to finding treatments for genitourinary system tumors and a range of other diseases. Jiangsu Yahong Meditech operates both within China and internationally, aiming to address unmet medical needs in the oncology and infectious disease sectors.

Products and Services

• APL-1202: An anti-tumor drug currently in Phase III clinical trial, APL-1202 is being developed for the treatment of non-muscle invasive bladder cancer. This promising treatment represents the company's commitment to addressing critical gaps in bladder cancer therapy.
• APL-1501: An oral MetAP inhibitor, APL-1501 is in Phase I clinical trial. It targets urinary system tumors and is also being evaluated for its effectiveness against drug-resistant urinary tract infections, potentially offering a new treatment avenue for patients with these challenging conditions.
• APL-1706: This agent drug, in Phase III clinical trial, is another innovative solution in development for the treatment of non-muscle invasive bladder cancer, underscoring the company’s focus on genitourinary malignancies.
• APL-1702: A photodynamic therapy product currently in Phase III clinical trial, APL-1702 is aimed at treating cervical high-grade squamous intraepithelial lesions caused by HPV infections. This product highlights the company's efforts in fighting HPV-related conditions.
• Targeted Protein Degraders: In the preclinical stage, these include ASN-1764, intended for the treatment of triple-negative breast cancer; ASN-1780, for metastatic castration-resistant prostate cancer; and APL-1901, for ER-positive breast cancer. These targeted therapies represent cutting-edge research and development, focusing on difficult-to-treat forms of cancer with the potential to significantly impact patient outcomes.
• APL-1401: Developed to treat moderately to severely active ulcerative colitis, APL-1401 showcases the company's expansion into gastrointestinal diseases, reflecting its broader commitment to improving patient health across multiple disease areas.
• ASN-1733: This product is in development to treat infections caused by Acinetobacter baumannii, a critical priority pathogen known for its antibiotic resistance. ASN-1733 signifies Jiangsu Yahong Meditech's venture into the infectious disease domain, underscoring its contribution to combating antibiotic resistance.